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Several methodologies exist to enumerate circulating tumor cells (CTCs) from the blood of cancer patients; however, most
methodologies lack high-resolution imaging, and thus, little is known about the cytomorphologic features of these cells. In this
study of metastatic colorectal cancer patients, we used immunoﬂuorescent staining with ﬁber-optic array scanning technology to
identifyCTCs,withsubsequentWright-GiemsaandPapanicolaustaining.TheCTCswerecomparedtothecorrespondingprimary
and metastatic tumors. The colorectal CTCs showed marked intrapatient pleomorphism. In comparison to the corresponding
tissue biopsies, cells from all sites showed similar pleomorphism, demonstrating that colorectal CTCs retain the pleomorphism
present in regions of solid growth. They also often retain particular cytomorphologic features present in the patient’s primary
and/or metastatic tumor tissue. This study provides an initial analysis of the cytomorphologic features of circulating colon cancer
cells, providing a foundation for further investigation into the signiﬁcance and metastatic potential of CTCs.
1.Introduction
The spread of cancer cells from the primary tumor site to
distant organs results in an incurable condition associated
with a high incidence of mortality [1]. Evidence indicates
that primary tumor cells gain access to the bloodstream,
thus becoming circulating tumor cells (CTCs) that travel
via the peripheral blood to sites anatomically distant from
the primary tumor. There they form secondary tumors,
eventually producing lethal metastases, the major cause of
treatment failure in cancer patients [2, 3].
Circulating epithelial cells (CEpiCs) have been detected
in the peripheral blood of patients with a variety of
metastatic epithelial malignancies at varying concentrations
using several diﬀerent methodologies [4–10]. In general,
CEpiCs can be identiﬁed (using immunoﬂuorescence assays)
viamonoclonalantibodiesdirectedagainstepithelial-speciﬁc
antigens, allowing them to be distinguished from normal
blood cells [11, 12]. In the setting of a patient with known
metastatic carcinoma, these circulating epithelial cells are
generally presumed to be circulating malignant tumor cells
bymostresearchersintheﬁeld.Supportforthispresumption
is emerging; research has demonstrated genomic changes of
single CEpiCs and that the cells are aneuploid, suggestive
evidence that these cells are indeed malignant [13–16]. For
the purpose of this study, we use cytologic features of the
CEpiCs and their correlation with the primary biopsies to
support their presumed malignancy and henceforth in this
report refer to these cells as CTCs.
The presence of CTCs has been shown to correlate
with poor prognosis and lower survival in metastatic
breast and colorectal cancer patients [17–20]. Limited pilot
studies have also indicated the utility of detecting CTCs
in metastatic colorectal patients although there is apparent2 Journal of Oncology
discrepancy in enumeration among various studies [4, 20,
21]. CTCs provide the link between the primary and
metastatic tumors [22] so identiﬁcation and characterization
of CTCs holds promising implications for the detection and
treatmentmanagementofmetastaticepithelialmalignancies.
Furthermore, isolation and characterization of these cells
will provide new insights on the biological mechanisms of
metastasis.
Most CTC detection methods depend on immuno-
magnetic separation and immunoﬂuorescent labeling of
epithelial-speciﬁc antigens such as epithelial cell adhesion
molecule (EpCam) and cytokeratin (CK); however, because
of methodologic limitations, cytologic details of the cells are
notdiscernible,anddetailedmorphologicstudiesandimages
of CTCs are limited [13, 22, 23]. Detailed description and
images of the morphologic types of CTCs found speciﬁcally
in metastatic colorectal patients are even more scant [23].
Much remains unknown about circulating tumor cells:
how they enter the bloodstream, how frequently they
are destroyed within the bloodstream, how they exit the
bloodstream, and whether each CTC has the same metastatic
potential, that is, the same potential for extravasation and
developmentintoanewtumorinametastaticsite[24].Thus,
mereenumerationofCTCsmustbeaugmentedbytheability
to study individual cells by additional morphologic and/or
molecular characterization that could provide clinically
useful information as well as aid in our understanding of the
metastatic process.
We have previously reported about an enrichment-free
immunoﬂuorescent staining protocol with ﬁber-optic array
scanning technology (FAST) to enumerate and characterize
CTCs found in metastatic cancer patients [5, 22, 25]. The
methodology allows for detailed cytomorphologic analysis,
a n dw eh a v ep r e v i o u s l yr e p o r t e dad e t a i l e dr e v i e wo f
circulating breast carcinoma cells. We now add circulating
colon cancer to the limited atlas of CTCs, with this small
series in which we cytomorphologically evaluate CTCs from
the blood of ﬁve metastatic colorectal cancer patients. Single
cells found in the blood are also compared to archived
histopathologic and cytologic specimens of the patient’s
primary and/or metastatic tumor.
2.MaterialsandMethods
2.1. Collection of Blood Samples. Five metastatic colorectal
cancer patients provided informed consent at Scripps Clinic
(La Jolla, CA) as approved by the Institutional Review Board.
From each patient, 8mL of peripheral blood was collected in
a Rare Cell blood collection tube (Streck, Omaha, NE) and
processed within 24 hours.
2.2. Immunoﬂuorescent Staining Protocol for Labeling CTCs.
Blood samples were subjected to an isotonic lysis with
ammonium chloride buﬀer (155mM NH4Cl, 10mM
KHCO3, 0.1mM EDTA, pH 7.4). After 5 minutes on a
rotator and a 5-minute centrifugation at 700g, the super-
natant containing lysed red blood cells was removed. The
resulting nucleated cell pellet was resuspended in phosphate
buﬀered saline (PBS) and distributed on custom-designed
adhesive slides (Marienfeld, Germany) that have an active
area of 62cm2 that can hold a monolayer of roughly 27
million nucleated cells. Slides were incubated at 37
◦Cf o r4 0
minutes.Cellswerethenﬁxedwith2%paraformaldehydefor
20 minutes, washed with PBS, and permeabilized with cold
methanol for 5 minutes, followed by another PBS wash step.
Subsequently, 10% goat serum was added for 20 minutes
to block nonspeciﬁc binding sites, followed by incubation
at 37
◦C with monoclonal antipan cytokeratin (Sigma, MO)
and conjugated CD45-Alexa647 (Serotec) antibodies for
40 minutes. After a PBS wash, the secondary antibody,
Alexa555 (Invitrogen), was added for 20 minutes. Cells were
counterstained with DAPI for 10 minutes and mounted with
an aqueous mounting media.
2.3. FAST Scanning and ADM-Coupled Imaging of
Immunoﬂuorescently Labeled CTCs. Fiber-optic Array
Scanning Technology (FAST) was used to identify the
location of CTCs as described previously [25]. Brieﬂy, an
argon-ion laser excites ﬂuorescence in labeled cells and
determines the location of a ﬂuorescently labeled cell by the
scan and stage positions at the time of emission at a scan rate
of 25 million cells per minute. Each FAST-identiﬁed object
was then imaged with a 20X objective in ﬂuorescence via
automated digital microscopy (ADM).
2.4. Relocation of CTCs for Morphological Analysis. A pathol-
ogist used 20X magniﬁcation and applied strict criteria
deﬁning CTCs as cytokeratin positive, CD45 negative, and
DAPI positive (nuclear stain). Enumeration of CTCs was
done at 20X for all patient specimens. To morphologically
evaluate ﬂuorescent CTCs for further cytologic details, 100X
images were taken. Subsequently, coverslips were removed
and the Wright-Giemsa stain and/or Papanicolau stain was
applied. Cells were then relocated using calibration ﬁducials
a n di m a g e di nb r i g h t ﬁ e l df o rf u r t h e rc y t o m o r p h o l o g i c
analysis (Figure 1).
2.5. Patient Analysis. Primary and metastatic tumor biopsies
were reviewed by a single pathologist. Architectural and
cytologic features of each primary tumor and available
metastatic tumor biopsies were reviewed. Patient status at
the time of the blood draw (stable disease versus progressive
disease) was determined by a blinded medical oncologist
review of lab data including CEA, radiology, and clinician
assessment of the patient around the time of draw.
3. Results
Patient and tumor characteristics are summarized in Table 1.
Patients varied in the number and types of metastases as well
astheirlineoftherapy;however,reviewoftheprimarytumor
slides demonstrated that all had presented with moderately
diﬀerentiated adenocarcinoma. When primary tissue and
metastatic tissue biopsies were available, all available tissue
biopsies were examined. These 5 patients had detectable
CTCs ranging from 12–282 per 8mL of blood. AlthoughJournal of Oncology 3
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Figure 1:RelocationandcharacterizationofCTCsusingtheWright-Giemsastain.AfterinitialidentiﬁcationofCTCsviaﬂuorescentimages,
subsequent Wright-Giemsa stain and/or Papanicolau stain of these cells is performed: (a) composite 3-color ﬂuorescent image, (b) DAPI
channel only, (c) cytokeratin channel only, (d) CD45 channel only, and (e) corresponding Wright-Giemsa-stained cell.
not a clinical outcomes study, we did note that patients who
wereidentiﬁedashavingprogressivediseasehadsigniﬁcantly
more cells than those patients who were stable at the time of
theblooddraw.Figure 2showsrepresentativeCTCs foundin
each patient.
3.1. Detailed Cytomorphologic Evaluation of CTCs. In the
peripheral blood, we found a markedly pleomorphic pop-
ulation of colon tumor cells as shown in the gallery of
colorectal CTCs (Figure 3). There were not only large, high
nuclear-to-cytoplasm (N/C) ratio cells (Figures 3(a) and
3(g)) but also cells with moderate to voluminous amounts
of cytoplasm, yielding moderate-to-low N/C ratios (Figures
3(e) and 3(f)). Overall CTC size also varied. Many were
larger than the surrounding benign WBCs (Figures 3(a),
3(f),a n d3(g)); however, there were also cells of the same
size or smaller than surrounding WBCs (Figures 3(c),
3(d),a n d3(e)). In some cases, the smaller cells showed
features suggestive of apoptosis, such as irregular nuclear or
cytoplasmic condensation or frank fragmentation into dense
rounded structures (Figure 3(e)).
Notable were frequent cells with irregular nuclear con-
tours, either large lobations or ﬁne irregularities (Figures
3(a) and 3(b)). Some of the nuclei with large lobations
appeared monocytoid in shape, or showed a half moon-
like conﬁguration (Figure 3(f)); the nuclear invagination
is occupied by cytokeratin-rich cytoplasm. In other cells,
the nuclear irregularities are on a smaller scale, yielding a
ﬁnely irregular nuclear contour to a generally round or oval
nucleus (Figure 3(c)); these features are best demonstrated
byhigh-poweredexaminationofPapanicolau-stainedcellsat
the microscope.
Eccentricity of the nuclear location within the cell cyto-
plasm is also a prominent feature in many of the circulating
colon cancer cells. While the cytoplasm extends circumfer-
entially around the nuclei, many cells show a cytoplasmic
bulge on one side, occupied by cytokeratin-rich cytoplasm
(Figures 3(c) and 3(d)). The corresponding Wright-Giemsa
and Papanicolau-stained cells demonstrate a “plasmacytoid”
appearance familiar to cytopathologists examining cytologic
preparations of various adenocarcinomas.
3.2. Detailed Architectural, Histologic, and Cytomorphologic
Review of Primary/Metastatic Tumor. All primary tumors in
this small series were classiﬁed as moderately diﬀerentiated,
with architectural features showing a predominance of
abnormal gland formation and only focal areas of sheet-like
growth. Figure 4 shows histology, cytology, and representa-
tive circulating tumor cells found in Patient E. This histology
is representative of all patients in our series. The glandular
lumens oftencontain necroinﬂammatory debris, the familiar
“dirty necrosis” of colon cancer. The abnormal glands
are formed by columnar cells with nuclear enlargement,
hyperchromatism, elongation, and stratiﬁcation. In some of
the less well-diﬀerentiated glands, the tumor cells approach
a cuboidal shape, but overall the predominant tumor cell
shape is columnar. Individual cells vary in size; although
most cells of the tumor are larger than any surrounding4 Journal of Oncology
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Figure 2: Representative CTCs found in Patients 1–5. Each column represents one patient’s CTCs: Red = cytokeratin, Green = CD45, and
Blue = DAPI.
Table 1: Patient tumor characteristics and circulating tumor cell count.
Patient Age/sex
Time since
diagnosis
(mon)
Primary tumor site Location
of metastases Line of therapy CTCs (no. per 8mL) Patient status
Patient 1 60/M 75 Colon Liver, LN, lungs,
bone, paraspinal 7th 282 Progressive
Patient 2 54/M 37 Colon Liver 4th 25 Stable
Patient 3 70/F 27 Colon Liver 1st 12 Stable
Patient 4 44/F 16 Rectum
Liver, lungs, LN
ovaries,
retroperitoneum
1st 23 Stable
Patient 5 66/F 87 Colon Liver, retroperitoneal,
lung, endometrium 9th 164 Progressive
benign cells, there is a marked range of cell size within the
tumor, and cells at the smaller range of cell size approach
that of neighboring histiocytes or other benign stromal
cells. N/C ratio is also quite variable within the tumor
cell population; while high N/C ratio cells are certainly
present, there are also abundant cells with moderate-to-low
N/C ratios due to their voluminous cytoplasmic domain.
Individual tumor nuclei also frequently show nuclear loba-
tion, and/or ﬁne nuclear irregularities, features more easily
appreciated in the cytology specimens from ﬁne needle
biopsies of metastases (Figure 4). Apoptotic or degenerating
individual tumor cells are frequently observed, as are mitotic
ﬁgures.
3.3. Cytomorphologic Comparison of CTCs to the Primary
and Metastatic Tumors. In comparison to the tissue biopsies
from both primary and metastatic tumor sites, the morpho-
logic cell mix of circulating colon tumor cells is similar in
its pleomorphism. Certain cytologic features noted in the
tissue biopsies, in particular prominent lobation of nuclear
contours, are clearly evident in the circulating population.
As well, ﬁne irregularity of nuclear membrane contours
noted in solid tissue samples persists in the circulating
population of tumor cells. Finally, colon tumor cells in
circulationshowamorphologictendencytowardeccentricity
of the cytokeratin-rich cytoplasm, while their solid tissue
counterparts appear columnar in shape.Journal of Oncology 5
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Figure 3: CTCs pleomorphism in the blood of metastatic colorectal patients using ﬂuorescent, Papanicolau, and Wright-Giemsa stains.
Representative types of CTCs identiﬁed in patient cohort. Left: ﬂuorescent-stained CTC; Red: Alexa555-cytokeratin, Green: Alexa 647-
CD45, and Blue: DAPI. (a)–(f) Right: corresponding CTC viewed with Papanicolau stain. (g), (h) Right: corresponding CTC viewed with
Wright-Giemsa stain.
4. Discussion
Comparison of primary and metastatic colon tumor cells to
circulating colorectal tumor cells shows marked congruence
of cytologic features between the tissue compartments
as illustrated in Figures 2–4. Histopathologically, these
tumors are moderately diﬀerentiated adenocarcinomas, with
columnar tumor cells forming abnormal glands; the nuclei
are irregularly contoured and frequently lobated. Cytolog-
ically, the primary and metastatic tumor deposits show
pleomorphism among the individual cells of the tumor
tissue. Circulating cells from these same patients retain6 Journal of Oncology
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Figure 4: Comparison of CTC morphology with biopsy histology and touch preparation cytology in a patient with metastatic colorectal
cancer. (a) Low-power histology of the liver metastasis from 1999 of Patient E (H & E, 20X). (b) High-power histology of the liver metastasis
from 1999 of Patient E (H & E, 110X oil). (c) High-power cytology of retroperitoneal metastasis from 2002 of Patient E (H&E Stain, 100X
oil). (d) High-power cytology of retroperitoneal metastasis from 2002 of Patient E (Wright-Giemsa stain, 100X oil). (e)–(g) CTCs identiﬁed
in the blood of Patient E in 2008.
this cytomorphology, showing overall pleomorphism with
variations in size, shape, and N/C ratios as well. The CTCs
show nuclear contour irregularity and lobation, with eccen-
trically located cytoplasm corresponding to a columnar-type
adenocarcinoma cell. This analysis supports the premises
that CTCs retain primary tumor cytologic characteristics
and that CTCs represent a random sampling of the many
phenotypic cell types present in the primary and metastatic
tumor deposits. The ﬁndings argue against the theory that
only particular subsets of tumor cells enter the peripheral
blood, such as very poorly diﬀerentiated “stem cell”-like
tumor cells, or only visibly dead/dying apoptotic tumor cells.
The ﬁndings support the possibility that circulating tumor
cells consist of a combination of passively “shed” cells with
little malignant potential and actively “migrating” cells that
areviableandmaygoontoformfurthermetastaticfoci[26].
In comparison to a previous morphologic study of CTCs
in breast cancer, the pleomorphism in the circulating popu-
lation of colorectal cancer is similar to the pleomorphism in
the circulating population in breast cancer. However, there
appear to be subtle, but appreciable cytologic diﬀerences
between the two cancer types; the circulating breast cancer
cells are generally round with circumferential cytoplasm,
while many of the circulating colon cancer cells appear
eccentric, with a cytoplasmic bulge on one side. The subtle
diﬀerencesinshapebetweenCTCsofthetwotumortypesare
felt likely to be a result of the cell shape of the original tumor
type. The cells of breast cancer are usually cuboidal rather
than columnar, and the corresponding detached CTCs show
evenlydistributedcytoplasmwithnodiscernibleeccentricity.
One can theorize that the more exaggerated the columnar
shape and/or basally oriented nuclei of the original tumor
cells, the more eccentric the cytoplasm will appear when
the cell detaches from the stroma and enters the circulation.
Future evaluation of additional cases of adenocarcinoma
where the primary tumor is either very well diﬀerentiated
or very poorly diﬀerentiated will serve to further address
this connection between the appearance of the cells in tissue
versus that in circulation.
Morphologic evaluation of the characteristics of circu-
lating tumor cells from diﬀerent malignancies including
patients with nonmetastatic disease will contribute to our
future understanding of the metastatic process. Further-
more, as CTC enumeration and characterization enter the
mainstream of cancer diagnostics and care, familiarity with
the appearance and variability of features of CTCs will be
important for pathologists. This small series demonstrates
that colon cancer cells in circulation are not dissimilar in
appearance from the cells in tissue within a single patient,
and that between tumor types, the cells in circulation mayJournal of Oncology 7
vary in their appearance. As new techniques for further
assessmentof the circulating component of epithelial tumors
emerge, these cells may serve as an easily accessible real-time
‘biopsy’ of the active tumor in a patient’s body.
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